{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:28:07Z","timestamp":1777894087020,"version":"3.51.4"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs), which can enhance antitumor immunity and inhibit cancer growth, have revolutionized the treatment of multiple cancers and dramatically decreased mortality. However, treatment with ICIs is directly associated with immune-related adverse events (irAEs) because of inflammation in off-target organs and autoimmunity resulting from non-specific immune activation. These irAEs can cause rheumatic diseases and manifestations such as inflammatory arthritis, polymyalgia rheumatica, myositis, vasculitis, Sicca and Sjogen's syndrome, and systemic lupus erythematosus. Early diagnosis and treatment of these adverse events will improve outcomes and quality of life for cancer patients. The treatment of rheumatic diseases induced by ICIs requires multidisciplinary cooperation among physicians. Furthermore, the underlying mechanisms are not fully understood and it is difficult to predict and evaluate these side effects precisely. In this review, we summarize available studies and findings about rheumatic irAEs, focusing mainly on the clinical manifestations, epidemiology, possible mechanisms, and guiding principles for treating these irAEs.<\/jats:p>","DOI":"10.3389\/fmed.2021.762247","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T06:17:05Z","timestamp":1636006625000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy"],"prefix":"10.3389","volume":"8","author":[{"given":"Pan","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhishuo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Ba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahui","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenghao","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1177\/1403494817715400","article-title":"The global cancer burden and human development: a review","volume":"46","author":"Fidler","year":"2018","journal-title":"Scand J Public Health."},{"key":"B2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.drudis.2019.11.003","article-title":"Immune checkpoint inhibitors: a promising anticancer therapy","volume":"25","author":"Singh","year":"2020","journal-title":"Drug Discov Today."},{"key":"B3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/cei.13081","article-title":"Immune checkpoint inhibitors: new strategies to checkmate cancer","volume":"191","author":"Wilson","year":"2018","journal-title":"Clin Exp Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1007\/s00520-016-3297-9","article-title":"The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review","volume":"24","author":"Atkinson","year":"2016","journal-title":"Support Care Cancer."},{"key":"B6","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.autrev.2018.01.010","article-title":"Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Tocut","year":"2018","journal-title":"Autoimmun Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.mcna.2020.09.009","article-title":"Rheumatic complications of immune checkpoint inhibitors","volume":"105","author":"Ghosh","year":"2021","journal-title":"Med Clin North Am."},{"key":"B8","doi-asserted-by":"publisher","first-page":"m736","DOI":"10.1136\/bmj.m736","article-title":"Autoimmune complications of immunotherapy: pathophysiology and management","volume":"369","author":"Chan","year":"2020","journal-title":"BMJ."},{"key":"B9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.clim.2013.11.007","article-title":"Do inhibitory immune receptors play a role in the etiology of autoimmune disease?","volume":"150","author":"Olde","year":"2014","journal-title":"Clin Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1182\/blood-2016-04-712612","article-title":"CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency","volume":"128","author":"Lo","year":"2016","journal-title":"Blood."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.immuni.2014.12.005","article-title":"The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells","volume":"41","author":"Sage","year":"2014","journal-title":"Immunity."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2017-211216","article-title":"Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment","volume":"76","author":"Belkhir","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nature14468","article-title":"T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection","volume":"523","author":"McKinney","year":"2015","journal-title":"Nature."},{"key":"B15","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nm.4321","article-title":"Is autoimmunity the Achilles' heel of cancer immunotherapy?","volume":"23","author":"June","year":"2017","journal-title":"Nat Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/annonc\/mdw181","article-title":"Biomarkers associated with checkpoint inhibitors","volume":"27","author":"Manson","year":"2016","journal-title":"Ann Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMc1703047","article-title":"Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade","volume":"376","author":"Esfahani","year":"2017","journal-title":"N Engl J Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"B19","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Invest."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s10067-020-05420-w","article-title":"Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift?","volume":"40","author":"Chatzidionysiou","year":"2021","journal-title":"Clin Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.rdc.2016.09.007","article-title":"Immune-related adverse effects of cancer immunotherapy- implications for rheumatology","volume":"43","author":"Cappelli","year":"2017","journal-title":"Rheum Dis Clin North Am."},{"key":"B22","doi-asserted-by":"publisher","first-page":"W992","DOI":"10.2214\/AJR.10.6198","article-title":"Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy","volume":"197","author":"Bronstein","year":"2011","journal-title":"AJR Am J Roentgenol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/ijc.32132","article-title":"A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors","volume":"145","author":"Arnaud-Coffin","year":"2019","journal-title":"Int J Cancer."},{"key":"B24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.semarthrit.2018.02.011","article-title":"Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen","volume":"48","author":"Cappelli","year":"2018","journal-title":"Semin Arthritis Rheum."},{"key":"B26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.lungcan.2017.04.007","article-title":"Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature","volume":"108","author":"Ruiz-Ba\u00f1obre","year":"2017","journal-title":"Lung Cancer."},{"key":"B28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/art.40745","article-title":"Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients","volume":"71","author":"Richter","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e000714","DOI":"10.1136\/rmdopen-2018-000714","article-title":"Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy","volume":"4","author":"Leipe","year":"2018","journal-title":"RMD Open."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1093\/rheumatology\/kew484","article-title":"Advances in positron emission tomography for the imaging of rheumatoid arthritis","volume":"56","author":"Narayan","year":"2017","journal-title":"Rheumatology (Oxford)."},{"key":"B32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/CJI.0000000000000060","article-title":"Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma","volume":"38","author":"Chan","year":"2015","journal-title":"J Immunother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e200032","DOI":"10.1001\/jamanetworkopen.2020.0032","article-title":"Use of magnetic resonance imaging to identify immune checkpoint inhibitor-induced inflammatory arthritis","volume":"3","author":"Subedi","year":"2020","journal-title":"JAMA Netw Open."},{"key":"B34","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/rheumatology\/kex470","article-title":"Metastatic joint involvement or inflammatory arthritis? a conundrum with immune checkpoint inhibitor-related adverse events","volume":"57","author":"Albayda","year":"2018","journal-title":"Rheumatology (Oxford)."},{"key":"B35","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/BOR.0000000000000601","article-title":"Arthritis risk with immune checkpoint inhibitor therapy for cancer","volume":"31","author":"Pundole","year":"2019","journal-title":"Curr Opin Rheumatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/CJI.0000000000000163","article-title":"Nivolumab causing a polymyalgia rheumatica in a patient with a squamous non-small cell lung cancer","volume":"40","author":"Bernier","year":"2017","journal-title":"J Immunother."},{"key":"B37","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jbspin.2016.01.007","article-title":"Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma","volume":"84","author":"Garel","year":"2017","journal-title":"Joint Bone Spine."},{"key":"B38","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.semarthrit.2017.03.003","article-title":"Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab","volume":"47","author":"Gauci","year":"2017","journal-title":"Semin Arthritis Rheum."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.semarthrit.2018.10.012","article-title":"Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: a single center experience","volume":"48","author":"Mooradian","year":"2019","journal-title":"Semin Arthritis Rheum."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e000906","DOI":"10.1136\/rmdopen-2019-000906","article-title":"Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature","volume":"5","author":"Calabrese","year":"2019","journal-title":"RMD Open."},{"key":"B41","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1158\/1078-0432.CCR-14-2468","article-title":"Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma","volume":"21","author":"Gibney","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/ane.13331","article-title":"Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies","volume":"143","author":"Wong","year":"2021","journal-title":"Acta Neurol Scand."},{"key":"B44","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jaut.2019.03.005","article-title":"Inflammatory myopathy associated with PD-1 inhibitors","volume":"100","author":"Seki","year":"2019","journal-title":"J Autoimmun."},{"key":"B45","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.semarthrit.2018.05.006","article-title":"Myositis as an adverse event of immune checkpoint blockade for cancer therapy","volume":"48","author":"Shah","year":"2019","journal-title":"Semin Arthritis Rheum."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology."},{"key":"B47","doi-asserted-by":"publisher","first-page":"101508","DOI":"10.1016\/j.eucr.2020.101508","article-title":"Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: a case report of successful management","volume":"34","author":"Yanase","year":"2021","journal-title":"Urol Case Rep."},{"key":"B48","doi-asserted-by":"publisher","first-page":"102455","DOI":"10.1016\/j.autrev.2019.102455","article-title":"Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern","volume":"19","author":"Matas-Garc\u00eda","year":"2020","journal-title":"Autoimmun Rev."},{"key":"B49","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12885-020-07741-0","article-title":"Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems","volume":"21","author":"Ma","year":"2021","journal-title":"BMC Cancer."},{"key":"B50","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13256-019-2105-9","article-title":"Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report","volume":"13","author":"Shibata","year":"2019","journal-title":"J Med Case Rep."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"R207","DOI":"10.1530\/EC-20-0342","article-title":"Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review","volume":"9","author":"Stelmachowska-Bana\u015b","year":"2020","journal-title":"Endocr Connect."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.3390\/ijms21093389","article-title":"Rheumatic manifestations in patients treated with immune checkpoint inhibitors","volume":"21","author":"Melissaropoulos","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors-a systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin Rheumatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1080\/09273948.2019.1610460","article-title":"Retinal vasculitis associated with ipilimumab","volume":"28","author":"Tsui","year":"2020","journal-title":"Ocul Immunol Inflamm."},{"key":"B57","doi-asserted-by":"publisher","first-page":"35","DOI":"10.5152\/eurjrheum.2019.19061","article-title":"Isolated testicular vasculitis due to immune checkpoint inhibitor","volume":"7","author":"Weiner","year":"2020","journal-title":"Eur J Rheumatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/cup.13562","article-title":"Interstitial granulomatous dermatitis and granulomatous arteritis in the setting of PD-1 inhibitor therapy for metastatic melanoma","volume":"47","author":"Singh","year":"2020","journal-title":"J Cutan Pathol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.ejim.2018.07.023","article-title":"Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: a case series","volume":"57","author":"Tomelleri","year":"2018","journal-title":"Eur J Intern Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1136\/annrheumdis-2018-213857","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors","volume":"78","author":"Roger","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1136\/annrheumdis-2016-210820","article-title":"Onset of connective tissue disease following anti-PD1\/PD-L1 cancer immunotherapy","volume":"77","author":"Le","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e235886","DOI":"10.1136\/bcr-2020-235886","article-title":"Durvalumab-associated vasculitis presenting as 'the blue toe syndrome'","volume":"13","author":"Gupta","year":"2020","journal-title":"BMJ Case Rep."},{"key":"B63","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jdcr.2018.03.013","article-title":"Nivolumab-induced systemic vasculitis","volume":"4","author":"Kang","year":"2018","journal-title":"JAAD Case Rep."},{"key":"B64","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/ced.14449","article-title":"De novo subacute cutaneous lupus erythematosus-like eruptions in the setting of programmed death-1 or programmed death ligand-1 inhibitor therapy: clinicopathological correlation","volume":"46","author":"Bui","year":"2021","journal-title":"Clin Exp Dermatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s12885-017-3313-6","article-title":"Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade","volume":"17","author":"Gambichler","year":"2017","journal-title":"BMC Cancer."},{"key":"B66","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12885-019-5661-x","article-title":"Acral vascular necrosis associated with immune-check point inhibitors: case report with literature review","volume":"19","author":"Khaddour","year":"2019","journal-title":"BMC Cancer."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1136\/annrheumdis-2018-213470","article-title":"Checkpoint inhibitor-associated immune arthritis","volume":"78","author":"Arnaud","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1136\/annrheumdis-2019-215819","article-title":"Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list?","volume":"80","author":"Raschi","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B69","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody-induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N Engl J Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"vii40","DOI":"10.1093\/rheumatology\/kez297","article-title":"Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy","volume":"58","author":"Abdel-Wahab","year":"2019","journal-title":"Rheumatology (Oxford)."},{"key":"B71","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14737140.2017.1296765","article-title":"Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review","volume":"17","author":"Abdel-Rahman","year":"2017","journal-title":"Expert Rev Anticancer Ther."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.autrev.2018.05.002","article-title":"Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: fasciitis with myositis syndrome as a new complication of immunotherapy","volume":"17","author":"Narv\u00e1ez","year":"2018","journal-title":"Autoimmun Rev."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","article-title":"Sicca syndrome associated with immune checkpoint inhibitor therapy","volume":"24","author":"Warner","year":"2019","journal-title":"Oncologist."},{"key":"B74","doi-asserted-by":"publisher","first-page":"e391","DOI":"10.1634\/theoncologist.2019-0467","article-title":"Sicca syndrome induced by immune checkpoint inhibitor therapy: optimal management still pending","volume":"25","author":"Ortiz","year":"2020","journal-title":"Oncologist."},{"key":"B75","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/14397595.2018.1532559","article-title":"Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy","volume":"29","author":"Ohnuma","year":"2019","journal-title":"Mod Rheumatol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"133","DOI":"10.7326\/L18-0209","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease","volume":"169","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","article-title":"Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity","volume":"75","author":"Gutzmer","year":"2017","journal-title":"Eur J Cancer."},{"key":"B79","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/art.40397","article-title":"Brief report: cancer immunotherapy in patients with preexisting rheumatic disease: the mayo clinic experience","volume":"70","author":"Richter","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2174\/1573397115666190119094736","article-title":"Immune checkpoint inhibitors-related rheumatic diseases: what rheumatologist should know?","volume":"15","author":"Gediz","year":"2019","journal-title":"Curr Rheumatol Rev."},{"key":"B82","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41584-018-0074-9","article-title":"Rheumatic immune-related adverse events from cancer immunotherapy","volume":"14","author":"Calabrese","year":"2018","journal-title":"Nat Rev Rheumatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer."},{"key":"B85","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4143\/crt.2020.790","article-title":"The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients","volume":"53","author":"Tang","year":"2021","journal-title":"Cancer Res Treat."},{"key":"B86","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.5301\/ejo.5000724","article-title":"A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab","volume":"26","author":"Abu","year":"2016","journal-title":"Eur J Ophthalmol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) Induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40425-018-0412-0","article-title":"Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis","volume":"6","author":"Johnson","year":"2018","journal-title":"J Immunother Cancer."},{"key":"B89","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40425-019-0577-1","article-title":"Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B90","doi-asserted-by":"publisher","first-page":"vii49","DOI":"10.1093\/rheumatology\/kez360","article-title":"Management of rheumatic complications of ICI therapy: a rheumatology viewpoint","volume":"58","author":"Leipe","year":"2019","journal-title":"Rheumatology (Oxford)."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.3390\/cancers12113446","article-title":"Multidisciplinary clinical approach to cancer patients with immune-related adverse events induced by checkpoint inhibitors","volume":"12","author":"Londo\u00f1o","year":"2020","journal-title":"Cancers (Basel)."},{"key":"B93","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","journal-title":"Science."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.762247\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T06:17:08Z","timestamp":1636006628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.762247\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,4]]},"references-count":93,"alternative-id":["10.3389\/fmed.2021.762247"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.762247","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,4]]},"article-number":"762247"}}